Clinical trials of allogeneic irradiated whole cell tumor vaccines encoding GM-CSF have been reported, with the theoretical potential that an allogeneic source of such an engineered tumor cell vaccine could provide an “off the shelf” consistent and well-characterized source of the therapeutic agent, but the best overall choice of genetically-engineered tumor cell vaccine remains to be determined [195]. This evidence concerns the gene CSF2 and neoplasm.